In vitro development of automatic control for the actively filled electrohydraulic heart

Measurement of Oxygen Consumption and Arterial-Venous Oxygen Saturation following Total Artificial Heart Implantation

Current algorithms for control of the total artificial heart are directed at maintaining hemodynamic homeostasis. Future control systems will also need to modify cardiac output in response to metabolic needs. This study was undertaken to evaluate oxygen metabolism monitoring as an indicator of the adequacy of organ and tissue perfusion. Following recovery from implantation of the Utah-100 pneumatic total artificial hearts, five calves (85 to 95 kg) underwent placement of fiberoptic oxymetry catheters to determine mixed venous and arterial oxygen saturations. By continuously measuring oxygen consumption with a gas analyzer, oxygen utilization and delivery were determined. In the awake calves, at-rest cardiac output was varied to produce hyperperfused and hypoperfused conditions while the adequacy of tissue perfusion was assessed with continuous mixed venous oxymetry and confirmed with serum lactate (Lact) levels. Inadequate tissue perfusion (Lact > 1.0 mmol/L) was evidenced by a mixed venous oxygen saturation <40%, oxygen delivery of < 200.0 milliliters/minute/m2), and oxygen delivery to utilization ratio of < 1.8 during the hypoperfusion conditions of the experiment. By accounting for oxygen consumption, the ratio of oxygen delivery to oxygen utilization was predictive of the adequacy of tissue perfusion. These results suggest that continuous oxygen metabolism monitoring may be useful as a physiologic control modifier to maintain total artificial heart output sufficient to meet physiologic needs, while avoiding hyperperfusion, unnecessary wear and deterioration of the implanted device due to excessive heart rates.

Different Stroke Volumes for the Left and Right Ventricles in the Moving-Actuator Type Total Artificial Heart

A new electromechanical moving-actuator type total artificial heart (TAH) has been developed to solve the imbalance problem without an extra compliance chamber. A different stroke volume was achieved by the large left sac size and the asymmetry of the actuator motion referred to the center position. The left ventricle consists of a double sac with the outer sac attached to the actuator providing active diastolic filling, while the double sac of the right ventricle being free from the actuator, and having sufficient suction produced due to the rigid pump housing. The stroke volume difference between the left and right sac is compensated through the air in the interventricular space of the variable volume (VV) space. Computer simulation based on the geometrical relationships between the blood sacs and the actuator was performed to simulate the physical mechanisms of the moving-actuator type TAH. Results were then compared with the measured pressure changes in various chambers of the pump and the stroke volume differences in mock circulation test. In two acute calf experiments, the balanced left and right atrial pressures were achieved in the moving-actuator type TAH without an extra compliance chamber

A New Automatic Cardiac Output Control Algorithm for Moving Actuator Total Artificial Heart by Motor Current Waveform Analysis

A new automatic cardiac output control algorithm for an implantable electromechanical total artificial heart (TAH) was developed based on the analysis of motor current waveform without using any transducer. The basic control requirements of an artificial heart can be described in terms of three features: preload sensitivity, afterload insensivity, and balanced ventricular output. In previous studies, transducers were used to acquire information on the hemodynamic states for automatic cardiac output control. However, such a control system has reliability problems with the sensors. We proposed a novel sensorless automatic cardiac output control algorithm (ACOCA) providing adequate cardiac output to the time-varying physiological demand without causing right atrial collapse, which is one of the critical problems in an active filling device. In vitro tests were performed on a mock circulatory system to assess the performance of the developed algorithm and the results show that the new algorithm satisfied the basic control requirements of the cardiac output response.

Past and Present of Total Artificial Heart Therapy: A Success Story

The totally artificial heart (TAH) is among the most prominent medical innovations of the 21^st century, especially due to the increasing population with end-stage heart failure. The progressive course of the disease, its resistance to conventional therapy, and the scarcity of hearts available for transplantation were the prime impetus for developing a TAH, especially when other options of mechanical circulatory assist devices are exhausted. In this review, we narrate the history of TAH, give an overview of its technology, and address the pros and cons of the currently available TAH models in light of published clinical experience.

Indirect Bronchial Shunt Flow Measurements in AbioCor Implantable Replacement Heart Recipients

Bronchial shunt flows in the recipients of the electrohydraulic AbioCor implantable replacement heart have been measured indirectly. A built-in compliance chamber accommodates the differential flow output required of the two ventricles of the AbioCor. An occluder mechanism regulates the flow differential. For a thoracic unit, given a beat rate, an occluder setting, and the pressure differentials across the replacement heart ventricles, the atrial pressure difference depends only on the level of shunt flow present in the vasculature. For a replacement heart recipient, the bronchial shunt is the dominant shunt flow. For patients implanted with the AbioCor, the beat rates and the occluder settings are known and the pressure differentials across the ventricles are estimated. Atrial pressures were measured using catheters. The bronchial shunt flow was deduced from in vitro characterization data based on these parameters. Available data from five patients in the ongoing clinical trial of AbioCor showed 0-1.4 L/minute bronchial shunt flows. Maximum variation for any individual patient was 1.1 L/minute.

Development of a microcontroller-based automatic control system for the electrohydraulic total artificial heart

An automatic physiological control system for the actively filled, alternately pumped ventricles of the volumetrically coupled, electrohydraulic total artificial heart (EHTAH) was developed for long-term use. The automatic control system must ensure that the device: 1) maintains a physiological response of cardiac output, 2) compensates for an nonphysiological condition, and 3) is stable, reliable, and operates at a high power efficiency. The developed automatic control system met these requirements both in vitro, in week-long continuous mock circulation tests, and in vivo, in acute open-chested animals (calves). Satisfactory results were also obtained in a series of chronic animal experiments, including 21 days of continuous operation of the fully automatic control mode, and 138 days of operation in a manual mode, in a 159-day calf implant.

Total artificial heart using neural and fuzzy controller

The aortic pressure (AoP) and pulmonary artery pressure (PAP) are important factors for the long-term survival of the patient receiving an implant of a total artificial heart (TAH). A new afterload regulation method using neural controllers has been developed for a moving actuator type TAH. Without any transducer, the proposed neural controller, based on the predetermined peak level of the motor current, regulates AoP by adjusting the actuator velocity. At the same time, a fuzzy controller based on expert knowledge prevents the PAP from being abnormally high. The proposed controller not only regulates the pump output on the maintenance of the normal AoP and PAP, but it also successfully controls the suction in the right heart. In vitro tests show that the proposed neural and fuzzy controllers effectively regulate AoP and PAP as well as prevent atrial suction.

A moving-actuator type electromechanical total artificial heart--Part II: Circular type and animal experiment

A new type of electromechanical total artificial heart (TAH) based on circular rolling-cylinder mechanism was developed to overcome critical problems in motor-driven artificial hearts such as large size and difficulties in fitting the heart to atrial remnants and arterial vessels. Its performance and reliability were evaluated in mock circulation and in an animal implant experiment. The total weight and volume of the pump is 650 g and 600 mL, respectively. This new pump was implanted in a calf for total heart replacement and 96 h of survival was achieved. The whole system, including pump, controller, and control algorithm performed well enough to improve the prospect of eventual clinical application of our TAH system.

A moving-actuator type electromechanical total artificial heart--Part I: Linear type and mock circulation experiments

A new type of motor-driven total artificial heart system with a moving-actuator mechanism has been developed. The prototype system consists of a brushless dc motor inside of a rolling-cylinder, two arc-shaped pusher-plates and two polyurethane sacs. The moving-actuator type electromechanical pump has structural advantages of small size and light weight, as compared to other reported motor-driven pumps with fixed-actuator mechanisms. The results of the mock circulation tests are reported in this paper with a cardiac output of 9 L/min at an aortic pressure of 120 mmHg and a heart rate of 120 bpm. The fulfillment of the basic control requirements of the artificial heart was also confirmed, i.e., preload sensitive and afterload insensitive cardiac output response and balanced right and left ventricular outputs.

An electric artificial heart for clinical use

Advances in microelectronics, high-strength magnets, and control system design now make replacement of the heart using an implantable, electrically powered pump feasible. The device described herein is a compact, dual pusher plate unit with valved polyurethane sac-type ventricles positioned at either end. The power unit consists of a small, brushless direct current motor and a motion translator. A microprocessor control system is used to regulate heart beat rate and provide left-right output balance. Bench studies lasting for as long as 1 year have been performed. Heart replacement with the electric heart has been performed in 18 calves since 1984. The longest survivor lived for more than 7 months. Among the causes of termination were component failure, thromboembolic complications, and bleeding. No major problem has been identified that precludes prolonged use of the electric heart. In the future the patient with end-stage heart disease will have an electric artificial heart as one therapeutic option.

Development of an implantable motor-driven assist pump system

A motor-driven artificial pump and its transcutaneous energy transmission (TET) system have been developed. The artificial pump consists of a high-speed dc brushless motor driving a ball screw and magnetic coupling mechanism between the blood pump and ball screw. The ball screw transfers high-speed rotary motion into low-speed rectilinear motion by a single component. Magnetic coupling enables active blood filling without applying an excess negative pressure to the pump. The transcutaneous transformer is formed from a pair of concave/convex ferrite cores. This design minimizes lateral motion of the external core. Information on motor voltage is transmitted through the skin by infrared pulses. The motor voltage is regulated by controlling the duty ratio of the square pulse supplied to the primary coil. Pump flow of 5.6 l/min was obtained with a mean outlet pressure of 100 mmHg at a drive rate of 100 bpm under preload of 15 mmHg. The performance of synchronous pumping has been very satisfactory. Continuous pumping was maintained by the backup battery in the case of interruption of TET. 24 W were transmitted by TET system with 78 percent of efficiency. Temperature rise of the internal core was 0.2 C. The developed system is promising as an implantable assist pump system.

Current status of permanent total artificial hearts

Pneumatic total artificial heats, although demonstrating utility as temporary mechanical circulatory support devices, have not demonstrated a great deal of promise as permanent cardiac replacements. The increasing number of patients who would be candidates for total heart replacement suggests a large role for a permanent implantable total artificial heart. To that end, the Pennsylvania State University is developing an electric motor-driven total artificial heart; the results with implants in calves are encouraging. In this device, a roller-screw mechanism is used to translate the rotation of a brushless direct-current motor into rectilinear motion of a pusher-plate assembly, which in turn empties the blood sacs. The total artificial heart of the future will function under automatic control without percutaneous leads, and this should provide the patient with a nearly normal life-style. Although further experimental efforts are necessary to prepare the device for clinical trials, the technology to provide a safe and reliable electric blood-pump system is at hand.